Q3 2016 Earnings Estimate for Sarepta Therapeutics Inc. (SRPT) Issued By Jefferies Group
Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Equities research analysts at Jefferies Group increased their Q3 2016 earnings estimates for Sarepta Therapeutics in a research report issued on Sunday. Jefferies Group analyst G. Wang now anticipates that the firm will post earnings of ($1.33) per share for the quarter, up from their prior forecast of ($1.38). Jefferies Group currently has a “Hold” rating and a $58.00 target price on the stock. Jefferies Group also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.16) EPS, FY2016 earnings at ($5.13) EPS and FY2017 earnings at $0.35 EPS.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the firm earned ($0.87) earnings per share.
Several other equities research analysts also recently issued reports on SRPT. Cowen and Company reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, August 15th. Janney Montgomery Scott raised shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $30.00 to $65.00 in a research note on Monday, September 19th. William Blair reissued an “outperform” rating and issued a $88.00 target price on shares of Sarepta Therapeutics in a research report on Sunday. Robert W. Baird reissued an “outperform” rating and issued a $23.00 target price on shares of Sarepta Therapeutics in a research report on Monday, July 18th. Finally, JMP Securities reissued an “underperform” rating and issued a $10.00 target price on shares of Sarepta Therapeutics in a research report on Sunday, July 24th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $54.86.
Sarepta Therapeutics (NASDAQ:SRPT) traded up 1.46% during trading on Wednesday, reaching $62.38. The company had a trading volume of 736,090 shares. The company’s market capitalization is $2.99 billion. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $63.73. The stock has a 50 day moving average price of $37.94 and a 200-day moving average price of $24.60.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Fund Advisors increased its stake in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the last quarter. State Street Corp increased its stake in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares during the last quarter. Commonwealth Equity Services Inc acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $302,000. National Planning Corp increased its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares during the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.
In related news, SVP David T. Howton sold 9,304 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $465,200.00. Following the sale, the senior vice president now directly owns 11,168 shares in the company, valued at approximately $558,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 40,179 shares of the business’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total transaction of $2,410,740.00. Following the completion of the sale, the chief executive officer now owns 117,162 shares in the company, valued at $7,029,720. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by insiders.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.